for educational and safety purposes
The classic *-racetam family, from piracetam onward; the cholinergic-leaning nootropics that started the whole category.
13 sourced · 10 reference
Phenylpiracetam (phenotropil, carphedon) is a phenylated derivative of piracetam, developed in Russia and used clinically as a nootropic, with reported effects on focus, physical endurance, and tolerance to cold and fatigue. The added phenyl group makes it considerably more potent than the parent racetam and confers a distinct mechanism, selective inhibition of the dopamine transporter, which is thought to underlie its stimulant-like, motivating properties. It was among the first cognitive enhancers prohibited in competitive sport, having been banned by anti-doping authorities in 1998.
Aniracetam is a fat-soluble member of the racetam family and one of the original ampakines, a positive allosteric modulator of AMPA-type glutamate receptors used as a cognition enhancer. By slowing the desensitization of these excitatory receptors it strengthens the synaptic transmission tied to learning and memory, and it has been used clinically abroad for cognitive symptoms after stroke and in dementia. Its principal metabolite, 2-pyrrolidinone, has been reported to produce a longer-lasting enhancement of AMPA-receptor function through a CaMKII-dependent pathway. It is also noted for anxiolytic and mood effects in animal models.
Coluracetam has the most distinctive proposed mechanism in the racetam family. Rather than acting at a receptor, it was designed to raise the rate at which neurons take up choline, the raw material the brain uses to build acetylcholine. Mitsubishi developed it in Japan in the 1990s as an Alzheimer's candidate, and it was later carried into depression research and through a completed 115-person trial. Readers who use it describe sharper focus and, unusually for a nootropic, changes in visual vividness. The evidence for the mechanism is narrower than the reputation: the choline-uptake effect was shown in animals whose cholinergic neurons had been deliberately lesioned first and not in normal tissue, and an independent group at Pfizer testing the same transporter across four separate methods found no effect at all. That lesion-dependence is itself worth understanding, because it would predict a quieter effect in a healthy brain rather than none. No human trial has yet reported a cognitive result; the 2009 study completed without publishing its outcomes.
Oxiracetam is a synthetic compound from the racetam family and a close chemical relative of piracetam; it was developed in Italy in the 1980s as a prescription drug for memory and attention problems in dementia. Older European trials in dementia patients generally reported small improvements on cognitive test scores, but the modern evidence is split: a 590-patient Chinese trial in traumatic brain injury found a real benefit, while a 500-patient Korean trial found none for preventing cognitive decline after stroke, and South Korea then withdrew the drug. Nobody has established how it works; a standard 19-target receptor screen found no measurable binding at concentrations up to 30 micromolar, and no binding constant for oxiracetam at any brain receptor exists in the published literature. It remains in clinical use in China and is sold elsewhere as an unapproved powder, with a mild side-effect record but no trial evidence at all that it improves cognition in healthy people.
Nefiracetam is a fat-soluble pyrrolidinone racetam that modulates cholinergic, glutamatergic, and calcium signaling. It potentiates neuronal nicotinic acetylcholine receptor currents at sub-nanomolar concentrations and enhances NMDA-receptor function and long-term potentiation through protein kinase C and CaMKII, giving it a pronounced pro-cognitive and neuroprotective profile in preclinical research; it has also been reported to reverse signaling deficits in a laboratory model of Rett syndrome. It has been studied for memory impairment, dementia, and post-stroke apathy and depression.
Fasoracetam is a racetam-class nootropic that acts on the glutamatergic and GABAergic systems; with repeated administration it up-regulates GABA-B and metabotropic glutamate (mGluR) receptors. It is one of relatively few racetams to have reached controlled human trials, having been evaluated in adolescents with attention-deficit hyperactivity disorder who carry variants in genes governing mGluR signaling. It remains an investigational compound and is not an approved medicine.
Piracetam is the original nootropic, the very compound for which the word 'nootropic' was coined, developed by Corneliu Giurgea in the late 1960s to enhance learning and memory [1]. A cyclic derivative of the neurotransmitter GABA, it has become the foundational template of the entire racetam family and remains one of the most widely studied cognitive enhancers in the world [1][4]. Prized for a remarkable safety record and effects that are most pronounced when brain function is impaired, piracetam supports memory, learning, and cerebral circulation, and is used clinically for cognitive decline, myoclonus, and stroke recovery [2][4][5].
RGPU-95 is an experimental compound studied in Russian pharmacological research as a structural analog of fenotropil, better known as phenylpiracetam, a nootropic of the racetam family. In animal experiments it has shown anxiety-reducing and antidepressant-like effects, in some measures exceeding those of its parent compound. It is an obscure investigational substance with essentially no human data, and it is not an approved medicine or recognized supplement ingredient anywhere.
Phenylpiracetam Hydrazide (fonturacetam hydrazide) is a structural variant of phenylpiracetam in which the racetam's amide group is replaced by a hydrazide, marketed as a next-generation twist on one of the most potent racetam nootropics [4]. Its appeal rests on the phenylpiracetam framework, a scaffold known for selective dopamine transporter inhibition and stimulant-like focus, endurance, and cold resistance [2][5]. It is sold strictly as a research chemical, and its own pharmacology has not been characterized in published human or animal studies, so its profile is inferred from the phenylpiracetam parent it is built upon [3][4].
Omaron is a fixed combination of 400 mg piracetam and 25 mg cinnarizine, sold across the CIS for cerebrovascular complaints and vertigo.
Vinpotropile is a Russian fixed combination of vinpocetine and piracetam sold for cerebrovascular complaints and memory problems.
Pramiracetam is a laboratory-made compound in the piracetam ("racetam") family, developed by Parke-Davis as CI-879 and later sold in a few European countries as a prescription memory drug under the brand name Pramistar. It is meant to improve memory and attention; in animals it reliably increases the rate at which brain cells take up choline, a building block of the memory-related signalling chemical acetylcholine, but no receptor that it binds to has ever been identified. Human evidence is thin: a small placebo-controlled trial in men with head injuries reported better delayed recall, and a study in healthy volunteers found it partly blunted drug-induced forgetting, while a trial in Alzheimer's disease found no benefit even at high doses. The entire published literature is roughly 40 papers, most of them small, decades old, or done in rodents, so confident claims that it strongly enhances cognition in healthy people are not supported by what has actually been measured.
Citicoline with piracetam is a combination of two nootropic compounds sometimes taken together for cognitive support. Citicoline, also called cytidine diphosphate choline, is a naturally occurring precursor used to build brain cell membranes and the neurotransmitter acetylcholine, while piracetam is a synthetic derivative of GABA and the original member of the racetam family. The pairing is popular in nootropic circles, although the two ingredients have been studied mainly on their own rather than as a fixed combination.
Aloracetam is an experimental nootropic compound that was investigated as a potential treatment for cognitive impairment, most notably Alzheimer's disease. It is often grouped with the racetam family of cognition agents, though its structure departs from the classic 2-pyrrolidinone racetams. The compound was never brought to market and holds no regulatory approval in any major jurisdiction [1][2].
Brivaracetam is a racetam-derivative antiseizure medication and an analog of levetiracetam, used as add-on therapy for focal, or partial-onset, seizures in people with epilepsy. It was rationally designed as a high-affinity, highly selective ligand of the synaptic vesicle glycoprotein SV2A, binding the target roughly 15 to 30 times more tightly than levetiracetam, and is associated in clinical use with a more favorable behavioral and psychiatric tolerability profile. Developed by the company UCB and marketed as Briviact, it received European and United States approval in 2016.
Cebaracetam is an experimental nootropic drug of the racetam family that was studied during the 1990s as a candidate treatment for cognitive and memory disorders [1]. In chemical terms it is a chlorinated, piperazinone-bearing analogue of phenylpiracetam, with the molecular formula C16H18ClN3O3 [2]. The compound advanced into phase II clinical trials, but its development was discontinued in 1995 and it was never marketed [1]. Its mechanism of action was never clearly defined.
Dimiracetam is a synthetic bicyclic compound of the racetam family, related to the nootropic drug piracetam. It was originally developed as a cognition enhancer but has attracted most of its research attention as a candidate treatment for neuropathic pain, showing broad and long-lasting activity in animal models of several nerve-pain conditions, including pain caused by chemotherapy; this activity is attributed to reduced release of the excitatory neurotransmitter glutamate. It remains an investigational agent and is not an approved medicine.
Doliracetam is an obscure synthetic compound of the racetam family, a group of acetamide-based substances studied for possible effects on cognition. Unlike the classic racetams built on a pyrrolidinone ring, it is chemically an oxindole derivative carrying an acetamide group. It was patented by the German pharmaceutical company Hoechst in the early 1980s as one of a series of compounds described as having neuroanabolic properties. Doliracetam never became an established medicine, and very little published research on it exists.
Dupracetam is an experimental nootropic of the racetam (pyrrolidinone) family, structurally related to piracetam. It was investigated in the late twentieth century for possible effects on learning and cognition, yet it was never developed into an approved medicine and remains an obscure research compound with only a sparse scientific literature.
Etiracetam is a synthetic compound of the racetam family and a close relative of piracetam. It is a racemic mixture whose biologically active enantiomer, the S-form, is levetiracetam, a widely used antiseizure medication; investigation of levetiracetam's mechanism led to the identification of the synaptic vesicle glycoprotein SV2A as its molecular target and as a novel class of antiepileptic drug target. Etiracetam itself was investigated for effects on memory and against seizures but was not marketed, with development focusing instead on its purified active enantiomer.
Methylphenylpiracetam (MPP) is a methylated analogue of phenylpiracetam developed at the Latvian Institute of Organic Synthesis, and its most studied stereoisomer, E1R, is a positive allosteric modulator of the sigma-1 receptor [1]. In mice, E1R enhances memory retention and reverses scopolamine-induced cognitive impairment without altering locomotor activity, effects abolished by the selective sigma-1 antagonist NE-100 [1]. Unlike its parent phenylpiracetam, which is primarily a dopaminergic psychostimulant, MPP is characterized as a non-stimulant cognition enhancer acting through sigma-1 chaperone signaling [1].
Nebracetam (development code WEB 1881 FU) is an investigational nootropic of the racetam family that was studied mainly in Japan as a potential cognition enhancer. Chemically a pyrrolidinone related to piracetam, it is distinguished from most racetams by acting as a direct agonist at the M1 muscarinic acetylcholine receptor, alongside pronounced cholinergic and neuroprotective effects in preclinical models of memory impairment and cerebral ischemia. It was explored in such models but did not become an approved medicine.
Rolziracetam was developed as CI-911 during the 1980s racetam research wave that piracetam's success touched off across European and American pharma chemistry, one of many cyclic-imide/pyrrolidinone analogs screened for "amnesia-reversal" activity against scopolamine-induced memory deficits in rodents, the field's standard nootropic assay at the time. It performed in that classic screening model and had its metabolic disposition characterized in animal studies, but like most second-generation racetams it never accumulated the human efficacy data needed to reach market. The entire racetam class shared the same problem: a diffuse, hard-to-pin-down mechanism that made regulatory approval an uphill argument, and once the pharmaceutical industry's attention moved to more mechanistically defined drug classes, compounds like rolziracetam simply stopped being worth developing further.
